21
Feb
An ongoing clinical trial is evaluating the ability of HPV E6- and E7-reactive TILs (HPV-TILs) to treat metastatic HPV-positive cancers[94]. immunotherapy relies on Orlistat the basic principle of mobilizing the sponsor immune system to fight against cancer cells. Numerous approaches have been attempted during the last several decades to harness the innate capabilities of the immune system to fight tumor. Despite the best efforts, however, only limited success has been accomplished in developing effective antitumor immunotherapies. The inability to overcome the immunosuppressive behavior of the tumor microenvironment is considered a major hurdle in the development of effective immunotherapies. With the…